Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
Identifieur interne : 003354 ( Main/Exploration ); précédent : 003353; suivant : 003355Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
Auteurs : Werner Poewe [Autriche] ; Erik Wolters [Pays-Bas] ; Murat Emre [Turquie] ; Marco Onofrj [Italie] ; Chuanchieh Hsu [États-Unis] ; Sibel Tekin [États-Unis] ; Roger Lane [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Cholinesterase, Cholinesterase Inhibitors (therapeutic use), Cognition (physiology), Dementia, Dementia (complications), Dementia (drug therapy), Double-Blind Method, Female, Humans, Long term, Longitudinal Studies, Male, Nervous system diseases, Neuropsychological Tests (statistics & numerical data), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Phenylcarbamates (therapeutic use), Rivastigmine, Time Factors, Treatment, Treatment Outcome, cholinesterase inhibitor, dementia, long term, rivastigmine.
- MESH :
- chemical , therapeutic use : Cholinesterase Inhibitors, Phenylcarbamates.
- complications : Dementia, Parkinson Disease.
- drug therapy : Dementia, Parkinson Disease.
- physiology : Cognition.
- statistics & numerical data : Neuropsychological Tests.
- Activities of Daily Living, Aged, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Time Factors, Treatment Outcome.
Abstract
In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20700
Affiliations:
- Autriche, Italie, Pays-Bas, Turquie, États-Unis
- Hollande-Septentrionale, New Jersey, Tyrol (Land)
- Amsterdam, Innsbruck
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C18
- to stream Istex, to step Curation: 001C18
- to stream Istex, to step Checkpoint: 001E13
- to stream PubMed, to step Corpus: 002E27
- to stream PubMed, to step Curation: 002E27
- to stream PubMed, to step Checkpoint: 002C46
- to stream Ncbi, to step Merge: 001502
- to stream Ncbi, to step Curation: 001502
- to stream Ncbi, to step Checkpoint: 001502
- to stream Main, to step Merge: 004667
- to stream PascalFrancis, to step Corpus: 001B84
- to stream PascalFrancis, to step Curation: 001137
- to stream PascalFrancis, to step Checkpoint: 001A28
- to stream Main, to step Merge: 004B23
- to stream Main, to step Curation: 003354
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FF4664716C5C713577D1CEB95BD89D6BD466E804</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20700</idno><idno type="url">https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C18</idno><idno type="wicri:Area/Istex/Curation">001C18</idno><idno type="wicri:Area/Istex/Checkpoint">001E13</idno><idno type="wicri:doubleKey">0885-3185:2006:Poewe W:long:term:benefits</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16229010</idno><idno type="wicri:Area/PubMed/Corpus">002E27</idno><idno type="wicri:Area/PubMed/Curation">002E27</idno><idno type="wicri:Area/PubMed/Checkpoint">002C46</idno><idno type="wicri:Area/Ncbi/Merge">001502</idno><idno type="wicri:Area/Ncbi/Curation">001502</idno><idno type="wicri:Area/Ncbi/Checkpoint">001502</idno><idno type="wicri:doubleKey">0885-3185:2006:Poewe W:long:term:benefits</idno><idno type="wicri:Area/Main/Merge">004667</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0244405</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B84</idno><idno type="wicri:Area/PascalFrancis/Curation">001137</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A28</idno><idno type="wicri:doubleKey">0885-3185:2006:Poewe W:long:term:benefits</idno><idno type="wicri:Area/Main/Merge">004B23</idno><idno type="wicri:Area/Main/Curation">003354</idno><idno type="wicri:Area/Main/Exploration">003354</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul University, Istanbul Faculty of Medicine, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Gabriele D'Annunzio University Foundation, Pescara</wicri:regionArea><wicri:noRegion>Pescara</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="456">456</biblScope><biblScope unit="page" to="461">461</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FF4664716C5C713577D1CEB95BD89D6BD466E804</idno><idno type="DOI">10.1002/mds.20700</idno><idno type="ArticleID">MDS20700</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Cholinesterase</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Cognition (physiology)</term><term>Dementia</term><term>Dementia (complications)</term><term>Dementia (drug therapy)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Long term</term><term>Longitudinal Studies</term><term>Male</term><term>Nervous system diseases</term><term>Neuropsychological Tests (statistics & numerical data)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Phenylcarbamates (therapeutic use)</term><term>Rivastigmine</term><term>Time Factors</term><term>Treatment</term><term>Treatment Outcome</term><term>cholinesterase inhibitor</term><term>dementia</term><term>long term</term><term>rivastigmine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinesterase Inhibitors</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cognition</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Neuropsychological Tests</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cholinesterase</term><term>Démence</term><term>Long terme</term><term>Parkinson maladie</term><term>Rivastigmine</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Italie</li><li>Pays-Bas</li><li>Turquie</li><li>États-Unis</li></country><region><li>Hollande-Septentrionale</li><li>New Jersey</li><li>Tyrol (Land)</li></region><settlement><li>Amsterdam</li><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name></region></country><country name="Turquie"><noRegion><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name></noRegion></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></region><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003354 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003354 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FF4664716C5C713577D1CEB95BD89D6BD466E804
|texte= Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
}}
| This area was generated with Dilib version V0.6.23. |  |